The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy
Clinical Kidney Journal · 04.12.2023 · 16 (Supplement_2) · ii9-ii18
DOI: 10.1093/ckj/sfad200 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Kidney Journal, online erschienen am 04.12.2023. Verfasst von See Cheng Yeo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, Tan Tock Seng Hospital, Singapore. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Otsuka America Pharmaceutical, Inc..
Abstract (Originalsprache)
Advances in our understanding of the pathogenesis of immunoglobulin A nephropathy (IgAN) have led to the identification of novel therapeutic targets and potential disease-specific treatments. Specifically, a proliferation-inducing ligand (APRIL) has been implicated in the pathogenesis of IgAN, mediating B-cell dysregulation and overproduction of pathogenic galactose-deficient IgA1 (Gd-IgA1). Animal and clinical studies support the involvement of APRIL in the pathogenesis and progression of IgAN. An elevated level of APRIL is found in IgAN when compared with controls, which correlates with the level of Gd-IgA1 and associates with more severe disease presentation and worse outcomes. Conversely, anti-APRIL therapy reduces pathogenic Gd-IgA1 and IgA immune complex formation and ameliorates the severity of kidney inflammation and injury. Genome-wide association studies in IgAN have identified TNFSF13 and TNFRSF13B, a cytokine ligand-receptor gene pair encoding APRIL and its receptor, respectively, as risk susceptibility loci in IgAN, further supporting the causal role of the APRIL signalling pathway in IgAN. Several novel experimental agents targeting APRIL, including atacicept, telitacicept, zigakibart and sibeprenlimab, are currently under investigation as potential therapies in IgAN. Preliminary results suggest that these agents are well-tolerated, and reduce levels of Gd-IgA1, with corresponding improvement in proteinuria. Further studies are ongoing to confirm the safety and efficacy of anti-APRIL approaches as an effective therapeutic strategy in IgAN.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Renal Medicine, Tan Tock Seng Hospital, Singapore.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
- Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
- John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK.
Förderung
- Otsuka America Pharmaceutical, Inc.
Zitieren
APA
Yeo, S. C., & Barratt, J. (2023). The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy. Clinical Kidney Journal, 16(Supplement_2), ii9-ii18. https://doi.org/10.1093/ckj/sfad200
Vancouver
Yeo SC, Barratt J. The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy. Clinical Kidney Journal. 2023;16(Supplement_2):ii9-ii18. doi:10.1093/ckj/sfad200
BibTeX
@article{Yeo2023,
author = {Yeo, See Cheng and Barratt, Jonathan},
title = {The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy},
journal = {Clinical Kidney Journal},
year = {2023},
volume = {16},
number = {Supplement_2},
pages = {ii9--ii18},
doi = {10.1093/ckj/sfad200}
}
EUVIMED